Search Results

Stevenage, 25th April 2023. Plasticell Ltd, a developer of stem cell technologies and advanced therapies, has announced today that it has entered into a strategic collaboration with Singapore-based LambdaGen.

Plasticell Ltd has announced that it has been contracted by the Ministry of Defence (MoD) in a pilot programme to develop regenerative medicines for the treatment of injuries resulting from combat or terrorism.

Plasticell, a developer of stem cell technologies and therapies, has announced it is leading a consortium of pioneering gene therapy groups.

Plasticell Ltd, a developer of stem cell technologies and regenerative medicines, has announced that the Advanced Stem Cell Training Network (ASCTN), a European research consortium in which the company is a partner organisation, has successfully bid for over €3,700,000 in funding from the European Union

The project is part of Plasticell’s hematopoietic cell therapy portfolio, which includes the expansion of hematopoietic stem cells and the manufacture of various blood cell types from pluripotent cell sources.

Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for use by GSK in its therapeutic research.